Antifungal Resistance: An Emerging Reality and A Global Challenge
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Fungi are important causes of disease among organisms in the plant and animal kingdoms, including humans [1]. Because the use of antifungals is widespread in both agriculture and modern medicine, the prevalence of resistant fungal infections has been on the rise. The problem of growing antifungal resistance is exacerbated by a paucity of new antifungal agents in development that have unique mechanisms of action [2]. Given the increasing number of patients with chronic immunosuppressing conditions who require antifungal therapy as part of their supportive care, there is growing concern that we may be approaching not only the postantibiotic era but also the postantifungal era [3]. The emergence of fungal infections with innate or acquired resistance to modern antifungals is the focus of this Journal of Infectious Diseases supplement. In a series of 7 articles authored by notable experts in this field [4–10], we visit different aspects of this complex area. I would like to highlight some of what I find to be intriguing questions in this dynamic field. Resistance in both Candida and Aspergillus species has become a global problem since the introduction and widespread use of triazoles in early 1990s [11]. Reports of non-Candida species resistant to azoles and of multidrug-resistant Candida species, such as Candida glabrata [12] or, lately, Candida auris [13], are increasing with alarming frequency. In addition, the emergence of Aspergillus species that are resistant to triazoles is particularly concerning because azoles are the only oral treatment option for prophylaxis and long-term treatment of invasive fungal disease [3]. Iatrogenic selection of resistance for both Candida and Aspergillus in the past was typically restricted to patients who received prolonged treatment courses in the setting of poor source control or persistent severe immunosuppression [14, 15]. More recently, azole-resistant aspergillosis has been reported on 4 continents [16] and has been hypothesized to be driven by agricultural use of azoles [3]. This creates a difficult problem because of the need for complex containment strategies that involve regulating the agricultural use of fungicidal agents. Some intriguing questions have emerged in the epidemiology of fungal resistance. Why is the prevalence of azole resistance in Aspergillus so variable between hospitals in the same region or between countries? Is this an artifact of suboptimal sampling and/or detection methods? Early experience has suggested that more-intensive and more-systematic approaches to detect azole resistance in institutions often equate with a higher prevalence of azole-resistant Aspergillus strains. Alternatively, are there unique ecological niches in the environment or patterns of spread of resistance through geoclimatic factors that are yet to be understood (eg, global warming, wind activity, patterns of migration by birds to different areas, as appears to be the case for multidrug-resistant bacteria) [17]. For example, infections by the multidrug-resistant fungus Scedosporium prolificans have been geographically restricted to countries such as Australia and Spain [18], and amphotericin B–resistant Aspergillus terreus has been described mainly in isolated centers of Austria and Texas [19]. Clearly, investment in robust epidemiological studies is urgently needed to understand the relative contributions of the environment, specific antifungal drug classes and individual drugs (including their pharmacokinetic and pharmacodynamic behavior), and, importantly, risk factors pertaining to specific hosts. Importantly, not all patients with immunosuppression are similar in terms of their risk for resistant fungal infections and the type of such infections they acquire. Some examples are telling. First, patient with chronic granulomatous disease and severe inherent defects in neutrophil function very rarely develop the resistant mold infection mucormycosis, and the amphotericin B–resistant organism Aspergillus nidulans is a typical pathogen only in these patients [20]. On the other hand, patients with other defects in neutrophil function, such as those receiving high doses of corticosteroids for treatment of chronic graft versus host disease following allogeneic stem cell transplantation, develop this infection, especially if they are hyperglycemic and have been exposed to antifungal agents that lack Mucorales activity [21]. Second, infections by Candida krusei [22] or Fusarium solani rarely spread beyond patients with leukemia and those who have undergone hematopoietic stem cell transplantation. Fungal diagnostic assays, including tests to ensure the timely diagnosis of a resistant fungal infection, are one of the most urgent needs in medical mycology. Having better diagnostic tests would increase the possibility of implementing an effective antifungal stewardship program that would allow physicians to better distinguish colonization (a setting in which resistance frequently
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 1×
“Reports of non-Candida species resistant to azoles and of multidrug-resistant Candida species, such as Candida glabrata [12] or, lately, Candida auris [13], are increasing with alarming frequency.”
BackgroundInfections Caused by Scedosporium spp
Cortez, K. J., Roilides, E., Quiroz-Telles, F., Meletiadis, J., Antachopoulos, C., Knudsen, T., Buchanan, W., Milanovich, J., Sutton, D. A., Fothergill, A., et al. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00039-07 · Cited by 786
Mechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647 · cited 12×
“Tremendous progress has been made in characterizing molecular and epigenetic mechanisms of resistance, especially in Candida and Aspergillus [32].”
BackgroundInfluentialVerweij, P. E., Chowdhary, A., Melchers, W. J. G., & Meis, J. F. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ885 · Cited by 561 · cited 2×
“Given the increasing number of patients with chronic immunosuppressing conditions who require antifungal therapy as part of their supportive care, there is growing concern that we may be approaching not only the postantibiotic era but also the postantifungal era [3].”
BackgroundAntifungal drug resistance of pathogenic fungi
Kontoyiannis, D. P., & Lewis, R. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08162-x · Cited by 553
Self-citationProspective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus
van der Linden, J. W. M., Arendrup, M. C., Warris, A., Lagrou, K., Pelloux, H., Hauser, P. M., Chryssanthou, E., Mellado, E., Kidd, S. E., Tortorano, A. M., et al. (2015) · Emerging Infectious Diseases · doi:10.3201/eid2106.140717 · Cited by 371
The evolution of drug resistance in clinical isolates of Candida albicans.
Ford, C. B., Funt, J. M., Abbey, D., Issi, L., Guiducci, C., Martinez, D. A., Delorey, T., Li, B. Y., White, T. C., Cuomo, C., et al. (2015) · eLife · doi:10.7554/elife.00662 · Cited by 348 · cited 1×
“breakthrough infection in patients with a past history of antifungals have multiple mechanisms of resistance or uncharacterized mechanisms of resistance [35] or tolerance that might involve organelles important for drug detoxification, such as mitochondria.”
BackgroundHealey, K. R., Zhao, Y., Perez, W. B., Lockhart, S. R., Sobel, J. D., Farmakiotis, D., Kontoyiannis, D. P., Sanglard, D., Taj-Aldeen, S. J., Alexander, B. D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11128 · Cited by 276 · cited 1×
“Reports of non-Candida species resistant to azoles and of multidrug-resistant Candida species, such as Candida glabrata [12] or, lately, Candida auris [13], are increasing with alarming frequency.”
BackgroundSelf-citationAntifungal drug resistance evoked via RNAi-dependent epimutations
Calo, S., Shertz-Wall, C., Lee, S. C., Bastidas, R. J., Nicolás, F. E., Granek, J. A., Mieczkowski, P., Torres-Martínez, S., Ruiz-Vázquez, R. M., Cardenas, M. E., et al. (2014) · Nature · doi:10.1038/nature13575 · Cited by 175
Defining the frontiers between antifungal resistance, tolerance and the concept of persistence
Delarze, E., & Sanglard, D. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.10.001 · Cited by 118 · cited 1×
“The relationship between tolerance and resistance is fascinating and incompletely understood [36, 37].”
Background
Cited by
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
Synergistic Effects Between Metal Nanoparticles and Commercial Antimicrobial Agents: A Review
Ribeiro, A. I., Dias, A. M., & Zille, A. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.1c03891 · Cited by 276
Pfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00840-19 · Cited by 80
Susceptibility testing of fungi to antifungal drugs
Sanguinetti, M., & Posteraro, B. (2018) · Journal of Fungi · doi:10.3390/jof4030110 · Cited by 55
Nishimoto, A. T., Wiederhold, N. P., Flowers, S. A., Zhang, Q., Kelly, S. L., Morschhäuser, J., Yates, C. M., Hoekstra, W. J., Schotzinger, R. J., Garvey, E. P., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00341-19 · Cited by 52
Metadata
- Authors
- Kontoyiannis, D. P.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-08-15
- Volume
- 216
- Issue
- suppl_3
- Pages
- S431-S435
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2750649777
- Cited by
- 76
- References
- 14
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antifungal Resistance: An Emerging Reality and A Global Challenge. https://app.cochat.ai/papers/10.1093/infdis/jix179
- The paper
- Kontoyiannis, D. P. (2017). Antifungal Resistance: An Emerging Reality and A Global Challenge. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jix179
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.